TDO2 and neoplasm: LPM3480226 (12, Figure 2, LY-01013) is a potent, selective dual inhibitor of IDO1 and TDO, developed by Luye Pharma Group Ltd. It targets the initial rate-limiting step in tryptophan metabolism to disrupt tumor-induced immunosuppression (Delving into the Latest Updatesb).